← 홈

Antibody

1,904개 · ADC 1085 · Antibody 5609 · CGT 2765 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,904개
AntibodyCSanofiPhase 3

REGN668 (Dupilumab SAR231893, Dupilumab SAR231893 (REGN668))

Prurigo Nodularis · Dermatitis Atopic

#DermatitisAtopic#Antibody#Phase3#인기#항체+5
효능 ORR 0.45%임상시험 70상태 ACTIVE
AntibodyJanssenPhase 2

intravitreal, 2.0mg/0.05ml (Infliximab, Infliximab (intravitreal, 2.0mg/0.05ml))

Uveitic Macular Edema; Intraocular Inflammation · Uveitic Macular Edema

#UveiticMacularEdema#Antibody#Phase2#인기#항체+4
효능 ORR 10%임상시험 70상태 DISCONTINUED
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab & Ipilimumab)

Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 61.3%임상시험 70상태 ACTIVE
AntibodyRocheApproved

Mabthera (Mabthera)

Rheumatoid Arthritis · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 84.7%임상시험 69상태 ACTIVE
AntibodyAbbViePhase 3

Humira (Adalimumab, Adalimumab (Humira))

Ankylosing Spondylitis · Focal Glomerulosclerosis

#FocalGlomerulosclerosis#Antibody#Phase3#인기#항체+5
효능 ORR 98.4%임상시험 68상태 ACTIVE
AntibodyRocheApproved

Omalizumab (Omalizumab)

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Chronic Rhinosinusitis (CRS) · Persistent Allergic Asthma

#PersistentAllergicAsthma#Antibody#Approved#인기#항체+5
임상시험 67상태 ACTIVE
AntibodyShanghai Shengdi Pharmaceutical…vedotin (RC48) in combinati…Phase 2

Adebrelimab (Adebrelimab)

Pancreatic Cancer · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#인기#항체+5
임상시험 66상태 RECRUITING
AntibodyHoffmann-La Rochevedotin plus bendamustine a…Phase 3

Glofitamab (Glofitamab)

Diffuse Large B Cell Lymphoma (DLBCL); High Grade B Cell Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase3#인기#항체+5
임상시험 66상태 RECRUITING
AntibodyElevation OncologyDeruxtecan]Phase 1

CYRAMZA® (Ramucirumab, Ramucirumab (CYRAMZA®))

Stomach Neoplasm; Gastrointestinal Neoplasms · Stomach Neoplasm

#StomachNeoplasm#Antibody#Phase1#인기#항체+5
효능 ORR 44.7%임상시험 66상태 DISCONTINUED
AntibodyTakedaPhase 2

Vedolizumab (Vedolizumab)

Ulcerative Colitis and Crohn's Disease · Colitis

#Colitis#Antibody#Phase2#인기#항체+5
효능 ORR 1%임상시험 66상태 ACTIVE
AntibodyAmgenPhase 3

Denosumab (Denosumab)

Postmenopausal Osteoporosis · Giant Cell Tumor of Bone

#GiantCellTumorofBone#Antibody#Phase3#인기#항체+4
효능 ORR 16.7%임상시험 65상태 ACTIVE
AntibodyAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodyNovartisPhase 3

Ofatumumab (Ofatumumab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Leukemia

#Leukemia#Antibody#Phase3#인기#항체+5
효능 ORR 78.4%임상시험 65상태 RECRUITING
AntibodyAkeso-drivenPhase 2

cadonilimab (cadonilimab)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#인기#항체+5
임상시험 65상태 RECRUITING
AntibodyBelfast Health and Social Care …Approved

Golimumab (Golimumab)

Psoriatic Arthritis; Psoriasis · Chronic Nonbacterial Osteomyelitis

#ChronicNonbacterialOsteomyelitis#Antibody#Approved#인기#항체+5
효능 ORR 0.27%임상시험 64상태 DISCONTINUED
AntibodyJanssenderuxtecan in ovarian cance…Phase 2

Remicade (Infliximab, Infliximab (Remicade))

COPD; Cachexia · Kawasaki Disease

#KawasakiDisease#Antibody#Phase2#인기#항체+5
임상시험 64상태 ACTIVE
AntibodyGenentech, Inc.Phase 3

Tiragolumab (Tiragolumab)

Multiple Myeloma; Non-Hodgkin Lymphoma · Urothelial Carcinoma

#UrothelialCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 64상태 ACTIVE
AntibodyRochePhase 3

atezolizumab (Tecentriq, Atezolizumab + Bevacizumab)

Venous Thrombosis · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 49.3%임상시험 63상태 RECRUITING
AntibodyMerckvedotin after avelumabPhase 1

pembrolizumab (Keytruda, Pembrolizumab (+) Berahyaluronidase alfa)

Advanced or Metastatic Solid Tumors · Metastatic Non-small Cell Lung Cancer

#MetastaticNon-smallCellLungCance#Antibody#Phase1#인기#항체+5
효능 ORR 65.1%임상시험 63상태 ACTIVE
AntibodyAstraZenecaPhase 2

durvalumab (Imfinzi, durvalumab and tremelimumab)

Prostate Cancer · HCC

#HCC#Antibody#Phase2#인기#항체+5
효능 ORR 48%임상시험 63상태 ACTIVE

4 / 96 페이지

← 이전다음 →